Naloxone Seems To Have Caused Confusions In Maine

naloxone pack

Naloxone or its nasal spray version, Narcan, seems to have caused confusions.

Naloxone, which may come to be more commonly known by its brand name Narcan, seems to have been the cause for confusions after the state of Maine passed a new law back in the spring.

Narcan is an over the counter anti-opioid nasal spray. The nasal formulation of the medication was designed so as to offer a faster, safer alternative to the injectable naloxone.

Naloxone is one of the first medications used in order to treat suspected opioid overdoses as it rapidly reverses the latter’s effects.

The intranasal naloxone was designed so as to offer a needle-free, easy-to-use product that can be handled by any family member or caregiver.

The product should be generally available to any first responder in a suspected opioid overdose case.

It first became available back in 2015 after it was approved by the U.S. Food and Drug Administration or the FDA. Its introduction was announced by the National Institutes of Health subdivision, the National Institute on Drug Abuse or NIDA.

Naloxone has since then come to be presented as a potentially life-saving drug as it should present the ability of countering the effects of opiate overdoses.

As the medicine has come to be considered as one of the easiest to use, most useful alternatives, the state of Maine passed a new law concerning it.

Back in late April 2016, Maine authorities passed a law directing the Board of Pharmacy to approve the Narcan sale rules.

Narcan, naloxone’s brand name, should as such come to be sold by pharmacists under new rulings, which would also make it an over the counter medicine.

As the Board was given a July 1, 2017, deadline, it has brought the new Narcan rules into discussion. Its December meetings will be concentrating on them as they have been noticed to have caused confusions.

The confusions have mostly come from pharmacists, as they are unsure about certain potential regulations and restrictions.

Concerned pharmacists are drawing to attention the age questions, as they are asking if the product has a sales age-limit.

They also questioning its usage, as they are unsure whether they should themselves proceed and administer naloxone.

Narcan has become a staple medicine in some state and county public authority and education institution offices.

As the number of opioid overdoses continues to rise, counties and states have started equipping all the aforementioned authorities and institutions with Narcan.

One other point of confusion amongst Maine pharmacists is whether they can come to refuse to sell the drug to a customer.

As these are a few of the questions and points of discussions raised by the law, some consider that the law revisit couldn’t have come soon enough.

Kenney Miller, who is a co-signer of the September revisit letter and a Heath Equity Alliance executive director, was reported to be amongst them.

According to Miller, the Board should revisit and clarify the law as its clearer form could come a long way in fighting opioid overdoses.

As Miller pointed out the rising number of overdose death reports and deaths, an easier to sell such medicine could help curb the rising national trend.

Image Source: Wikimedia